Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Handa PharmaceuticalsROCO:6620 +1.36%81 EV-to-EBIT is 33.20 as of Sep. 21, 2026, which is 65% above its 10-year median of 20.14. GuruFocus rates ROCO:6620 with a GF Score™ of 81/100 and a GF Value™ of NT$123.24 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 682 Drug Manufacturers companies, Handa Pharmaceuticals ranks worse than 75.07% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Handa Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was NT$11,943 Mil.
Handa Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$618 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Handa Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Handa Pharmaceuticals's EV-to-EBIT falls into.
Handa Pharmaceuticals's current Enterprise Value is NT$20,528 Mil.
Handa Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$618 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Handa Pharmaceuticals (ROCO:6620) has a EV-to-EBIT of 33.20 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Handa Pharmaceuticals and its competitors. This is 65% above median its historical median of 20.14. According to the industry distribution chart, Handa Pharmaceuticals ranks #512 out of 682 companies in the Drug Manufacturers industry, placing it in the top 75.1%.
Is Handa Pharmaceuticals' EV-to-EBIT too high?
Handa Pharmaceuticals' current EV-to-EBIT of 33.20 is 65% above median its 10-year median of 20.14. The Drug Manufacturers industry median EV-to-EBIT is 16.08. Handa Pharmaceuticals' value of 33.20 is 106.5% above this industry median. Based on the distribution chart, Handa Pharmaceuticals ranks #512 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Handa Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Handa Pharmaceuticals ranks #512 out of 682 companies for EV-to-EBIT. This places Handa Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 16.08. Handa Pharmaceuticals' value of 33.20 is 106.5% above this benchmark. While the company's 10-year median is 20.14 vs. the industry median of 16.08, Handa Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Handa Pharmaceuticals's current EV-to-EBIT of 33.20 is 106.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Handa Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Handa Pharmaceuticals's current EV-to-EBIT is 33.20, which is 65% above median its own 10-year median of 20.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$123.24, compared to a current price of NT$149.00 — trading 20.9% above its estimated fair value. The current EV-to-EBIT is 33.20, which is 65% above median its 10-year median of 20.14 and 106.5% above the Drug Manufacturers industry median of 16.08. Handa Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current EV-to-EBIT is 33.20 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?
Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$149.00 is trading 20.9% above its estimated GF Value™ of NT$123.24.
GuruFocus considers Handa Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6620:
EV-to-EBIT: 33.20 (65% above median its 10-year median of 20.14)
GF Value™: NT$123.24 vs. price of NT$149.00 (20.9% above fair value)
Industry Position: 106.5% above the Drug Manufacturers median (#512 of 682)
No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
81GF Score
Get the complete analysis for ROCO:6620
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6620 has been successfully added to your 
